Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 8/2007

01-08-2007 | Original Article

Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity

Authors: Stephen R. Mattarollo, Tony Kenna, Mie Nieda, Andrew J. Nicol

Published in: Cancer Immunology, Immunotherapy | Issue 8/2007

Login to get access

Abstract

Combinations of cellular immune-based therapies with chemotherapy and other antitumour agents may be of significant clinical benefit in the treatment of many forms of cancer. Gamma delta (γδ) T cells are of particular interest for use in such combined therapies due to their potent antitumour cytotoxicity and relative ease of generation in vitro. Here, we demonstrate high levels of cytotoxicity against solid tumour-derived cell lines with combination treatment utilizing Vγ9Vδ2 T cells, chemotherapeutic agents and the bisphosphonate, zoledronate. Pre-treatment with low concentrations of chemotherapeutic agents or zoledronate sensitized tumour cells to rapid killing by Vγ9Vδ2 T cells with levels of cytotoxicity approaching 90%. In addition, zoledronate enhanced the chemotherapy-induced sensitization of tumour cells to Vγ9Vδ2 T cell cytotoxicity resulting in almost 100% lysis of tumour targets in some cases. Vγ9Vδ2 T cell cytotoxicity was mediated by perforin following TCR-dependent and isoprenoid-mediated recognition of tumour cells. Production of IFN-γ by Vγ9Vδ2 T cells was also induced after exposure to sensitized targets. We conclude that administration of Vγ9Vδ2 T cells at suitable intervals after chemotherapy and zoledronate may substantially increase antitumour activities in a range of malignancies.
Literature
1.
Baird RD, Kaye SB (2003) Drug resistance reversal—are we getting closer? Eur J Cancer 39(17):2450–2461PubMedCrossRef
2.
Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–729PubMedCrossRef
3.
Bonneville M, Fournie JJ (2005) Sensing cell stress and transformation through Vgamma9Vdelta2 T cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect 7(3):503–509PubMedCrossRef
4.
Carding SR, Egan PJ (2002) Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2(5):336–345PubMedCrossRef
5.
Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Raera C, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharm 42:1228–1236CrossRef
6.
7.
Clezardin P, Ebetino FH, Fournier PG (2005) Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65(12):4971–4974PubMedCrossRef
8.
Conti L, Casetti R, Cardone M, Varano B, Martino A, Belardelli F, Poccia F, Gessani S (2005) Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol 174(1):252–260PubMed
9.
Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, Bonneville M, Jotereau F (2005) V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol 175(8):5481–5488PubMed
10.
Coxon FP, Thompson K, Rogers MJ (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6:1–6CrossRef
11.
Dalton JE, Howell G, Pearson J, Scott P, Carding SR (2004) Fas–Fas ligand interactions are essential for the binding to and killing of activated macrophages by gamma delta T cells. J Immunol 173(6):3660–3667PubMed
12.
Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies M, Bukowski JF (2001) MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 15:83–93PubMedCrossRef
13.
Das H, Wang L, Kamath A, Bukowski JF (2001) Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98(5):1616–1618PubMedCrossRef
14.
Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O’Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D (2005) Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 23(18):4110–4116PubMedCrossRef
15.
Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR (2002) Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 23(1):14–18PubMedCrossRef
16.
Garcia VE, Sieling PA, Gong GH, Barnes PF, Uyemura K, Tanaka Y, Bloom BR, Morita CT, Modlin RL (1997) Single cell analysis of gammadelta T cell response to nonpeptide mycobacterial antigens. J Immunol 159:1328–1335PubMed
17.
Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G (2003) Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197(2):163–168PubMedCrossRef
18.
Green AE, Lissina A, Hutchinson SL, Hewitt RE, Temple B, James D, Boulter JM, Price DA, Sewell AK (2004) Recognition of nonpeptide antigens by human Vgamma 9Vdelta 2 T cells requires contact with cells of human origin. Clin Exp Immunol 136:472–482PubMedCrossRef
19.
Green JR (2003) Antitumor effects of bisphosphonates. Cancer Suppl 97(3):840–847
20.
Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T (1999) Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 96(12):6879–6884PubMedCrossRef
21.
Huber SA (2000) T cells expressing the gamma delta T cell receptor induce apoptosis in cardiac myocytes. Cardiovasc Res 45(3):579–587PubMedCrossRef
22.
Kabelitz D, Wesch D, Pitters E, Zoller M (2004) Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol 173(11):6767–6776PubMed
23.
Kabelitz D, Wesch D, Pitters E, Zoller M (2004) Potential of human gammadelta T lymphocytes for immunotherapy of cancer. Int J Cancer 112(5):727–732PubMedCrossRef
24.
Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N (2001) Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol 167(9):5092–5098PubMed
25.
Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K, Yagita H (1999) Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 162:2639–2647PubMed
26.
Knight LA, Conroy M, Fernando A, Polak M, Kurbacher CM, Cree IA (2005) Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay. Anticancer Drugs 16(9):969–976PubMedCrossRef
27.
Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M (2000) Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96(2):384–392PubMed
28.
Kunzmann V, Wilhelm M (2005) Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma 46(5):671–680PubMed
29.
Lafont V, Liautard J, Sable-Teychene M, Sainte-Marie Y, Favero J (2001) Isopentenyl pyrophosphate, a mycobacterial non-peptidic antigen, triggers delayed and highly sustained signaling in human gamma delta T lymphocytes without inducing down-modulation of T cell antigen receptor. J Biol Chem 276(19):15961–15967PubMedCrossRef
30.
Lake RA, Robinson BWS (2005) Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5:397–405PubMedCrossRef
31.
Lang F, Peyrat MA, Constant P, Davodeau F, David-Ameline J, Poquet Y, Vie H, Fournie JJ, Bonneville M (1995) Early activation of human V gamma 9V delta 2 T cell broad cytotoxicity and TNF production by nonpeptidic mycobacterial ligands. J Immunol 154(11):5986–5994PubMed
32.
Lieberman J (2003) The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal. Nat Rev Immunol 3(5):361–370PubMedCrossRef
33.
Linck D, Lentini G, Tiemann M, Fauser AA, Parwaresch R, Basara N (2005) Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma. Leuk Lymphoma 46(2):285–288PubMedCrossRef
34.
Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD (2005) Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J Urol 173(5):1552–1556PubMedCrossRef
35.
Lopez RD (2002) Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases. Immunol Res 26(1–3):207–221PubMedCrossRef
36.
Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, Foglietta M, Palumbo A, Coscia M, Castella B, Bruno B, Bertieri R, Boano L, Boccadoro M, Massaia M (2005) Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 19(4):664–670PubMed
37.
Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, Sato K, Nogawa M, Tanaka F, Maekawa T, Wada H (2005) Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47:31–39PubMedCrossRef
38.
Mattarollo SR, Kenna T, Nieda M, Nicol AJ (2006) Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Valpha24(+) NKT cell-mediated cytotoxicity. Int J Cancer 119(7):1630–1637PubMedCrossRef
39.
Mattarollo SR, Kenna T, Nieda M, Nicol AJ (2006) Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to Valpha24(+) NKT cell-mediated cytotoxicity. Int J Cancer 119:1630–1637PubMedCrossRef
40.
Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC (2003) Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 17(6):1068–1077PubMedCrossRef
41.
Neville-Webbe HL, Evans CA, Coleman RE, Holen I (2006) Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumor Biol 27:92–103CrossRef
42.
Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 113:364–371PubMedCrossRef
43.
Podack ER, Lowrey DM, Lichtenheld M, Hameed A (1988) Function of granule perforin and esterases in T cell-mediated reactions. Components required for delivery of molecules to target cells. Ann N Y Acad Sci 532:292–302PubMedCrossRef
44.
Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann T (2005) Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol 175(4):2144–2151PubMed
45.
Rosen LS (2002) Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors. Semin Oncol 6(Suppl 21):28–32CrossRef
46.
Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100(12):2613–2621PubMedCrossRef
47.
Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J, Nogawa M, Yuasa T, Kiyono Y, Wada H, Maekawa T (2005) Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 116(1):94–99PubMedCrossRef
48.
Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, Guiraud M, Monsarrat B, Saulquin X, Maillet S, Esteve JP, Lopez F, Perret B, Collet X, Bonneville M, Champagne E (2005) Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22(1):71–80PubMedCrossRef
49.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792PubMedCrossRef
50.
Spada FM, Grant EP, Peters PJ, Sugita M,Melian M, Leslie DS, Lee HK, van Donselaar E, Hanson DA, Krensky AM, Majdic O, Porcelli SA, Morita CT, Brenner MB (2000) Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. J Exp Med 191(6):937–948PubMedCrossRef
51.
Ullen A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kalkner KM, Lennernas B, Nilsson S (2005) Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncologica 44:644–650PubMedCrossRef
52.
Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, Caignard A (2005) Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. J Immunol 174(3):1338–1347PubMed
53.
Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruedier T, Tony H-P (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1):200–206PubMedCrossRef
54.
Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1):200–206PubMedCrossRef
55.
Zgani I, Menut C, Seman M, Gallois V, Laffont V, Liautard J, Liautard JP, Criton M, Montero JL (2004) Synthesis of prenyl pyrophosphonates as new potent phosphoantigens inducing selective activation of human Vgamma9Vdelta2 T lymphocytes. J Med Chem 47(18):4600–4612PubMedCrossRef
Metadata
Title
Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity
Authors
Stephen R. Mattarollo
Tony Kenna
Mie Nieda
Andrew J. Nicol
Publication date
01-08-2007
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 8/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-007-0279-2

Other articles of this Issue 8/2007

Cancer Immunology, Immunotherapy 8/2007 Go to the issue

Original Article

Assessment of CD4+  T cells specific for the tumor antigen SSX-1 in cancer-free individuals

Meeting Report

International conference: progress in vaccination against cancer-2006 (PIVAC 6), Granada, Spain

Original Article

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

Original Article

Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN

Original Article

NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo

Original Article

[F-18]-Fluoro-2-deoxy-d-glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits